Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,014 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Adjuvant therapy Clear all
Completed Not applicable Interventional

Improving Well-Being for Breast Cancer Patients

NCT02707471
View directory record Official record
Conditions
Self-management Intervention (SM-AET), General Health Education
Interventions
SM-AET, general health education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older · Female only
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 21, 2026, 1:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

NCT03405792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, WHO Grade IV
Interventions
Temozolomide (TMZ), Optune System, Pembrolizumab
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors

NCT01978964
View directory record Official record
Conditions
Solid Tumors
Interventions
ONT-10
Biological
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 21, 2026, 1:32 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

NCT06732401
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
192
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Brief Online Study Abroad Alcohol Intervention

NCT03928067
View directory record Official record
Conditions
Alcohol Abuse
Interventions
PNF + SAF
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years to 25 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer

NCT01407107
View directory record Official record
Conditions
Rectal Cancer
Interventions
Nitroglycerin 0.2 MG/HR, Nitroglycerin 0.4 MG/HR, Nitroglycerin 0.6 MG/HR
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 21, 2026, 1:32 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

NCT04748419
View directory record Official record
Conditions
Lung Cancer, Carcinoma, Non-Small Cell Lung
Interventions
consolidative hypofractionated radiation therapy (hfRT), Durvalumab 50 MG/ML
Radiation · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Non-invasive Spinal Stimulation as an Adjuvant Therapy for Trunk Control After Pediatric SCI

NCT05091463
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Biostim-5/Neostim transcutaneous spinal stimulator
Device
Lead sponsor
University of Louisville
Other
Eligibility
3 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Active, not recruiting Phase 3 Interventional

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Granada Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Active, not recruiting Phase 2 Interventional

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
Drug · Procedure · Biological + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
999
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

NOLAN: Naproxen or Loratadine and Neulasta

NCT01712009
View directory record Official record
Conditions
Bone Pain in Stage I - III Breast Cancer
Interventions
Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
83
States / cities
Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

NCT00918047
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
SPN-804O
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Little Rock, Arkansas • Loxahatchee Groves, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 1:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy

NCT01765218
View directory record Official record
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Topiramate, Placebo
Drug
Lead sponsor
Kristin R Hoffman
Other
Eligibility
Up to 6 Hours
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00348140
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
49
States / cities
Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

NCT00313560
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00089024
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 21, 2026, 1:32 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

NCT04291950
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsy
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 21, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

NCT06953882
View directory record Official record
Conditions
HER2 Negative Breast Cancer
Interventions
Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Genomics in Michigan Impacting Observation or Radiation

NCT02783950
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher Prostate Cancer Classifier
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
13
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 21, 2026, 1:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

NCT00838578
View directory record Official record
Conditions
Colorectal Cancer
Interventions
KRN330, Irinotecan
Biological · Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

NCT00470574
View directory record Official record
Conditions
Breast Cancer
Interventions
QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 21, 2026, 1:32 PM EDT